Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

Blood

Volumn 99, Issue 8, 2002, Pages 2670-2676

  Mount, Jane D ^a,b   Herzog, Roland W ^a,b   Michael Tillson, D ^b   Goodman, Susan A ^a,b   Robinson, Nancy ^a,b   McCleland, Mark L ^a,b   Bellinger, Dwight ^a,b   Nichols, Timothy C ^a,b   Arruda, Valder R ^a,b   Lothrop Jr , Clinton D ^a,b   High, Katherine A ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AAV (APOE)4 HAAT; AAV (APOE)4 HAAT CFIX; ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DNA VECTOR; DOSE RESPONSE; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEMOPHILIA B; LIVER; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKAGE;

EID: 0037089331     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.8.2670     Document Type: Article

References (35)

1. Gene transfer as an approach to treating hemophilia
2. Gene therapy and the hemophilias
3. Canine hemophilia B resulting from a point mutation with unusual consequences
4. A coagulation factor IX-deficient mouse model for human hemophilia B
5. A deletion mutation causes hemophilia B in Lhasa Apso dogs
6. The molecular basis of hemophilia A and B
7. Factor IX: Molecular structure, epitopes, and mutations associated with inhibitor formation
8. Haemophilia B mutations in Sweden: A population-based study of mutational heterogeneity
9. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
10. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
11. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
12. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
13. Adeno-associated viral vectors as gene delivery vehicles
14. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in context of a large factor IX gene deletion
15. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation
16. Advances toward gene therapy for hemophilia at the millennium
17. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy
18. Adeno-associated virus vectors can be efficiently produced without helper virus
19. Improvements in AAV vector production: Elimination of pseudo-wild type AAV
20. The molecular basis of canine pyruvate kinase deficiency
21. The kinetics of rAAV integration in the liver
22. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
23. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs
24. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
25. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX
26. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice
27. Human F.IX corrects the bleeding diathesis of mice with hemophilia B
28. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver
29. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA
30. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells
31. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance
32. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
33. Local control of the immune response in the liver
34. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors
35. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: Implications for gene therapy